FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* 2. Date of Event Requiring Statement (Month/Day/Year) 1. Name and Address of Reporting Person* 10/18/2016 | | tement | 3. Issuer Name and Ticker or Trading Symbol <u>CRISPR Therapeutics AG</u> [CRSP] | | | | |
|--|--|--------------------|--|---|------------------------------------|--|---|
| (Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC. | | | 4. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owne | | (Month/Day/Year) | | |
| 200 SIDNEY STREET | | | Officer (give title below) | Other (spe below) | | icable Line) | /Group Filing (Check |
| (Street) CAMBRIDGE MA 02139 | | | | | X | | y One Reporting Person y More than One erson |
| (City) (State) (Zip) | | | | | | | |
| Table I - Non-Derivative Securities Beneficially Owned | | | | | | | |
| 1. Title of Security (Instr. 4) | | | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | | ature of Indirect Beneficial Ownership rr. 5) | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | |
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise | 5. Ownership Form: Direct (D) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | Price of Derivative Security | Direct (D) or Indirect (I) (Instr. 5) | |
| Series A-3 Preferred Shares | (1) | (1) | Common Shares | 2,354,050 | (1) | I | See footnotes ⁽²⁾⁽³⁾ |
| Series B Preferred Shares | (1) | (1) | Common Shares | 191,764 | (1) | Ι | See footnotes ⁽²⁾⁽³⁾ |

Explanation of Responses:

1. These securities are convertible on a one-for-one basis at any time into shares of the Issuer's Common Shares at the holder's election and automatically upon the closing of the Issuer's initial public offering into the number of shares of Common Shares shown in column 3 above. These securities do not have an expiration date.

2. These shares are held by Abingworth Bioventures VI, LP ("Abingworth"). Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VILLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth GP. Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The reporting person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.

3. (Continued from Footnote 2) This report shall not be deemed an admission that the reporting person, Abingworth or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Remarks:

/s/ Kurt von Emster

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

SEC Form 3

10/18/2016 Date